Last reviewed · How we verify
Medication augmentation
At a glance
| Generic name | Medication augmentation |
|---|---|
| Also known as | Prazosin is the first choice agent in this Arm |
| Sponsor | Massachusetts General Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Design, Development and Evaluation of a Digital Health Assistant for Paediatric Asthma
- Hydroxyethyl Starch Versus Crystalloid and Postoperative Major Adverse Kidney Complications (PHASE4)
- Radiographical, Histomorphometrical and Biomarker Analysis After Maxillary Sinus Augmentation Utilizing Xenograft Particulate Bone Graft Mixed With Parathyroid Hormone (PHASE4)
- Scaffold-guided Breast Implant Revision Surgery (NA)
- Comparative Effects of Functional Electrical Stimulation and Mirror Therapy for Foot Clearance Among Patients With Sub-acute Stroke (NA)
- Pattern Separation in Major Depressive Disorder (PHASE1)
- HYDRAFIL-D: HYDRogel Augmentation For Intervertebral Lumbar Discs (NA)
- The Influence of Chemotherapy on Position Sense
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Medication augmentation CI brief — competitive landscape report
- Medication augmentation updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI